Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
出版年份 2023 全文链接
标题
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-10-22
DOI
10.1016/j.annonc.2023.10.122
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
- (2023) Mafalda Oliveira et al. JOURNAL OF CLINICAL ONCOLOGY
- AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2023) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
- (2023) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
- (2022) Joseph J. Zhao et al. BMC Medical Research Methodology
- Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy
- (2022) François-Clément Bidard et al. CANCER RESEARCH
- Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
- (2022) Miguel Martín et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
- (2022) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- (2022) Francois-Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
- (2022) M.P. Goetz et al. ANNALS OF ONCOLOGY
- 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
- (2022) M. Martin Jimenez et al. ANNALS OF ONCOLOGY
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
- (2022) François-Clément Bidard et al. LANCET ONCOLOGY
- Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
- (2022) Dominic Wei Ting Yap et al. JAMA Oncology
- Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
- (2021) Hao Liao et al. Frontiers in Oncology
- IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves
- (2021) Na Liu et al. BMC Medical Research Methodology
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials
- (2020) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
- (2020) M. Martin et al. ANNALS OF ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 mutations in breast cancer
- (2019) Derek Dustin et al. CANCER
- Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors
- (2019) Mariana F Leal et al. CLINICAL CANCER RESEARCH
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials
- (2019) Omar Najim et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA damage repair defects as a new class of endocrine treatment resistance driver
- (2018) Meenakshi Anurag et al. Oncotarget
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started